Efgartigimod Alfa

CHEMBL4297551 Phase 4 Disetujui Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A neonatal Fc receptor (FcRn) blocker that reduces the levels of harmful IgG antibodies in the blood, used to treat generalized myasthenia gravis. By lowering the antibodies that attack muscle receptors, it helps reduce muscle weakness.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A neonatal Fc receptor (FcRn) blocker that reduces the levels of harmful IgG antibodies in the blood, used to treat generalized myasthenia gravis. By lowering the antibodies that attack muscle receptors, it helps reduce muscle weakness.

Yes, Efgartigimod Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297551. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Mencari informasi yang ramah bagi pasien?

Efgartigimod Alfa di PillFYI

Data Cepat

Sinonim: 2

Tautan Eksternal

ChEMBL CHEMBL4297551

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.